Hairpin Technologies announced that the U.S. Patent & Trademark Office denied all 4 petitions filed by Benitec Biopharma seeking to invalidate Cold Spring Harbor Laboratory patents covering short hairpin RNA (shRNA). The denial supports the validity of CSHL's shRNA patent portfolio, which Hairpin Technologies represents. CSHL and Hairpin Technologies authorize the use of the shRNA technology through non-exclusive licensing agreements.
The Kusuma Yearbook for 2015 highlights our achievements in India over the last three years since the start of the Kusuma Schools Partnership Initiative began.
Come Trasformarsi da Imprenditore Incasinato a Imprenditore soddisfatto(Infog...Salvatore Castro
Trasformati in 5 Mosse da imprenditore incasinato a imprenditore soddisfatto. Come fare oggi, quando sia chi è un imprenditore, sia chi svolge qualsiasi altra professione, a non incasinarsi mentre si è impegnati a correre di qua e di là? Qui racconto la mia esperienza personale e come ho fatto io in prima persona.
Debbie Kirkland is a Realtor in Tallahassee, Florida. She participates in multi-media marketing, is a member of local and state associations and active in the Tallahassee community. Take a look at some of Debbie's listings and open house opportunities.
The Kusuma Yearbook for 2015 highlights our achievements in India over the last three years since the start of the Kusuma Schools Partnership Initiative began.
Come Trasformarsi da Imprenditore Incasinato a Imprenditore soddisfatto(Infog...Salvatore Castro
Trasformati in 5 Mosse da imprenditore incasinato a imprenditore soddisfatto. Come fare oggi, quando sia chi è un imprenditore, sia chi svolge qualsiasi altra professione, a non incasinarsi mentre si è impegnati a correre di qua e di là? Qui racconto la mia esperienza personale e come ho fatto io in prima persona.
Debbie Kirkland is a Realtor in Tallahassee, Florida. She participates in multi-media marketing, is a member of local and state associations and active in the Tallahassee community. Take a look at some of Debbie's listings and open house opportunities.
For more details on our products and services, please feel free to visit us at guldhalsband, silverörhängen & guldringar
For more details visit :- http://www.misterbling.se/
En el concepto de Pedagogía Hospitalaria (UPH) conviene tener presente cuatro ideas clave: que la humanización actúa como epicentro de la atención sanitaria, especialmente desde el siglo XXI, que la Pedagogía Hospitalaria cabe considerarla como una sección más del Servicio de Pediatría, que la Pedagogía Hospitalaria está más allá de la Medicina y más allá de la Educación Especial y que la Pedagogía Hospitalaria es mucho más que un aula hospitalaria, pues su labor se extiende más allá de sus paredes.
Esta breve descripción de las actividades de la UPH del Hospital General Universitario de Alicante sirven para remarcar la vitalidad de la misma, con el motor de la ilusión y de convertirse en instrumento terapéutico y docente, totalmente integrado en el Servicio de Pediatría. Porque pensamos que la UPH es una buena punta de lanza y una oportunidad para iniciar el camino de “hospital líquido”, entendiendo como tal aquél que sale de sus paredes y convive con la sociedad. Porque la UPH es un paradigma para humanizar la enseñanza y la asistencia sanitaria.
This document is being provided by PetLife solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this document
as constituting either an offer to sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and
disclosure of information including important information regarding risks and conflicts of interest contained in the Company's final offering memorandum and related
documents, the only basis on which subscriptions may be made.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
For more details on our products and services, please feel free to visit us at guldhalsband, silverörhängen & guldringar
For more details visit :- http://www.misterbling.se/
En el concepto de Pedagogía Hospitalaria (UPH) conviene tener presente cuatro ideas clave: que la humanización actúa como epicentro de la atención sanitaria, especialmente desde el siglo XXI, que la Pedagogía Hospitalaria cabe considerarla como una sección más del Servicio de Pediatría, que la Pedagogía Hospitalaria está más allá de la Medicina y más allá de la Educación Especial y que la Pedagogía Hospitalaria es mucho más que un aula hospitalaria, pues su labor se extiende más allá de sus paredes.
Esta breve descripción de las actividades de la UPH del Hospital General Universitario de Alicante sirven para remarcar la vitalidad de la misma, con el motor de la ilusión y de convertirse en instrumento terapéutico y docente, totalmente integrado en el Servicio de Pediatría. Porque pensamos que la UPH es una buena punta de lanza y una oportunidad para iniciar el camino de “hospital líquido”, entendiendo como tal aquél que sale de sus paredes y convive con la sociedad. Porque la UPH es un paradigma para humanizar la enseñanza y la asistencia sanitaria.
This document is being provided by PetLife solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this document
as constituting either an offer to sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and
disclosure of information including important information regarding risks and conflicts of interest contained in the Company's final offering memorandum and related
documents, the only basis on which subscriptions may be made.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
Top 10 companies using CRISPR technologyARUNPANDIAN07
The revolutionary gene editing tool CRISPR/Cas9 has reached its height because of its accuracy and easy-to-design. Several gene corrections have been made by scientists in vitro and in vivo.
For more information, visit, www.theblackchalk.com
CureDuchenne and Sarepta Therapeutics host webinar to provide Duchenne patients, caregivers and advocates a comprehensive review of Sarepta’s RNA-targeted technology platforms (PMO and PPMO). Gilmore O’Neill, M.B., M.M.Sc., Chief Medical Officer of Sarepta, will present along with Debra Miller, CEO and Founder of CureDuchenne.
1. [1]
Contact: Paul Sheiffele Hairpin Technologies Inc.
Phone: 631-881-0844 2200 Smithtown Avenue
Email: info@hairpintech.com Ronkonkoma, NY 11779
Web: www.hairpintechnologies.com
For Immediate Release:
April 7, 2016
Hairpin Technologies Announces U.S. Patent Office Denial Of All 4 Petitions Filed by Benitec
Biopharma Against Cold Spring Harbor Laboratory’s Short Hairpin RNA (shRNA) Patents
USPTO Action Supports Validity of the shRNA Patent Portfolio Represented by Hairpin Technologies
Ronkonkoma, NY; April 7, 2016: Hairpin Technologies announced today that the U.S. Patent &
Trademark Office has denied all 4 petitions filed by Benitec Biopharma Ltd seeking to invalidate Cold
Spring Harbor Laboratory (CSHL) patents covering short hairpin RNA (shRNA). Invented at CSHL by Dr.
Gregory Hannon and his team, shRNA is a versatile research tool used in functional genomics and drug
discovery which can be used to silence target gene expression to help elucidate biological function and
identify novel drug targets. The technology is particularly useful in determining the role of specific genes
in disease, allowing researchers to observe what happens when these genes are turned off. In addition
to determining how these genes function, shRNA may also help scientists identify and validate novel
drug targets for which new pharmaceuticals can be developed.
“We are happy with the result, but are not surprised,” said Dr. Bruce Stillman, President and Chief
Executive Officer of the Laboratory. “CSHL vigorously defended its patents against these challenges. Dr.
Gregory Hannon and his team, through their pioneering work at CSHL, are recognized around the world
for having developed shRNA to knock down gene expression in mammalian cells. Benitec’s claims to the
contrary were rejected by the Patent Office. We look forward to enhancing our shRNA licensing program
with this well-deserved confirmation by the Patent Office of CSHL’s key role in this technology.”
The shRNA technology is already commercially available from a number of authorized distributors with
existing non-exclusive license agreements from CSHL and Hairpin Technologies to make, market and sell
shRNA. Pharmaceutical and biotechnology companies of all sizes, as well as contract research
organizations which utilize shRNA, are also required to obtain a non-exclusive license from CSHL for
approved access to the relevant intellectual property.
Established in March 2015, Hairpin Technologies maintains the sole authority to negotiate and execute
license agreements with potential licensees for all non-therapeutic uses of the relevant U.S. and
international patents covering the shRNA technology. The company leads ongoing marketing, corporate
outreach and out-licensing efforts on behalf of CSHL, and it recently executed commercial distributor
licenses with Sigma-Aldrich and Life Technologies/Thermo-Fisher, as well as commercial end-user
licenses with Biogen, Epizyme, GlaxoSmithKline, Johnson & Johnson, and ORIC Pharmaceuticals,
surpassing $1M in licensing revenue within the first year of operations.
About Cold Spring Harbor Laboratory
Celebrating its 125th anniversary in 2015, Cold Spring Harbor Laboratory has shaped contemporary
biomedical research and education with programs in cancer, neuroscience, plant biology and
quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs
1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program hosts
more than 12,000 scientists from around the world each year on its campuses in Long Island and in
2. [2]
Suzhou, China. The Laboratory’s education arm also includes an academic publishing house, a graduate
school and programs for middle and high school students and teachers. For more information,
visit www.cshl.edu
About Hairpin Technologies: Hairpin Technologies Inc. was founded in 2015 to expand the commercial
distribution and research use of short hairpin RNA (shRNA), a versatile biomedical research and drug
discovery tool invented at Cold Spring Harbor Laboratory (CSHL). As the exclusive licensing agent of
CSHL, the mission of Hairpin Technologies is to negotiate and execute license agreements with
manufacturers, distributors and end-users of the shRNA technology, which is protected by a robust
portfolio of U.S. and international patents. In this capacity, Hairpin Technologies leads ongoing
marketing, corporate outreach and out-licensing efforts to identify and engage potential licensees on
behalf of CSHL. For more information, visit www.hairpintechnologies.com.